
How to Finally Treat Acne Scars (Without Wasting Time or Money)
The good news: Today's acne scar treatments are more effective, personalized, and safer than ever. The key is knowing what type of scars you have and how to match them with the most appropriate therapy.
Understanding Your Acne Scars
Not all acne scars are the same. Each type responds differently to treatment, so accurate identification is an important first step.
Ice pick scars: Deep, narrow scars that resemble small puncture marks. Often considered one of the most challenging types to treat. Think V-shaped.
Boxcar scars: Broad, well-defined depressions with sharp edges, commonly seen on the cheeks and temples. Think U-shaped.
Rolling scars: Shallow, wave-like indentations caused by bands of scar tissue pulling down the skin.
Hypertrophic or keloid scars: Raised, thickened scars often found on the chest, shoulders, or jawline.
Post-inflammatory hyperpigmentation (PIH) or erythema (PIE): Red or dark discoloration that remains after acne resolves, especially common in skin of color. While technically not a true scar, they can feel like it!
Accurate diagnosis leads to more successful outcomes and avoids the trial and error that can waste both time and money.
There Is No Universal 'Fix'
Despite online claims, no single product or procedure treats every type of acne scar. Treatment needs to be customized based on scar type, skin tone, and individual goals. Be cautious of 'miracle' solutions or overly aggressive procedures that promise dramatic results overnight.
Evidence-Based Treatments That Work
Here are some of the most effective, dermatologist-approved methods:
Subcision and Laser-Assisted Subcision
Ideal for rolling scars, subcision involves releasing the fibrous bands beneath the skin that cause depressions. When combined with laser therapy, it also stimulates collagen for smoother skin.
Microneedling With Radiofrequency
This combines fine needles with thermal energy to remodel skin and improve texture. It is a preferred option for moderate scarring and has minimal downtime.
TCA CROSS (Chemical Reconstruction of Skin Scars)
This technique uses a high-strength acid like TCA or phenol, applied directly into ice pick scars to stimulate collagen production. It's highly targeted and effective for deep, narrow scars.
Laser Resurfacing
Ablative lasers like CO2 or erbium can improve skin texture and depth of scarring. Caution is advised for people with darker skin tones to reduce the risk of pigmentation issues.
Topical Treatments for Pigmentation
When scars leave behind discoloration, the following options can be effective:
Broad-spectrum sunscreen used daily
Tretinoin to increase skin turnover and collagen boosting
Brightening agents such as vitamin C, niacinamide, azelaic acid, and tranexamic acid
Lasers and chemical peels may also be used as a second step, once inflammation has resolved.
Don't Overlook Fillers and Biostimulatory Treatments
For certain types of depressed acne scars – like rolling or boxcar scars – injectables can offer fast and visible improvement. These are especially helpful when used alongside other treatments like subcision or microneedling.
Here's how they work:
Hyaluronic acid fillers: Add immediate volume to lift indented scars and smooth the skin's surface. Results are visible right away and can last six to 12 months.
Biostimulatory injectables (like Sculptra or Radiesse): They do more than just fill. These stimulate your skin's natural collagen production for gradual, longer-lasting improvement, and they're especially useful in combination treatments.
Combination therapy: This is often used after subcision to hold the skin up and prevent the scar from tethering down again.
While not a permanent fix, fillers can be a powerful tool in your acne scar treatment plan, especially if you're looking for quicker wins while working on long-term skin texture.
Address Active Acne First
Scar treatments are only effective when active acne is controlled. Initiating scar therapy while breakouts continue can undermine results and increase the risk of complications. Begin by managing active acne to set the foundation for long-term skin health.
Set Realistic Expectations
While complete scar removal is unlikely, significant improvement – often 30% to 50% – is achievable. These changes can make a major difference in how the skin looks and feels, contributing to greater self-confidence and comfort.
Navigating the world of acne scar treatments can be overwhelming. With an accurate diagnosis, evidence-based therapies, and a personalized approach, real and lasting improvement is possible.
Rather than chasing quick fixes, focus on progress. The skin has an impressive ability to heal with the right support – and your path to smoother, more confident skin may be closer than you think.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment
We recently compiled a list of Vertex Pharmaceuticals Incorporated stands second on our list and has recently launched the first non opioid acute pain treatment. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a global biotech firm based in Boston, is known for developing innovative treatments for serious diseases like cystic fibrosis, sickle cell disease, and beta thalassemia. The company is recognized for its strong pipeline targeting unmet medical needs. In July 2025, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) launched JOURNAVX (suzetrigine), a first-in-class, non-opioid treatment for moderate-to-severe acute pain. JOURNAVX, an oral NaV1.8 pain signal inhibitor, was named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc. It represents the first new class of pain medicine in decades and offers a safer alternative to opioids by directly targeting pain pathways without addiction risks. This launch marks a major advancement in pain management, aligning with public health efforts to reduce opioid use. JOURNAVX is especially relevant for acute pain scenarios such as post-surgical recovery and injury care. A closeup of pills in a pharmacy, representing the high quality medications of the company. Beyond acute pain, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) continues to expand its reach. Its next-gen cystic fibrosis therapy, ALYFTREK, received approval from the European Commission in July 2025, strengthening its global leadership in this area. The company is also advancing gene-editing therapies like CASGEVY for sickle cell and beta thalassemia, and is developing treatments for kidney disease, type 1 diabetes, and rare genetic disorders. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
a minute ago
- Yahoo
Elevance Health, Inc. (ELV) Downgrades 2025 Earnings Amid Rising Medical Costs
We recently compiled a list of Elevance Health, Inc. stands third on our list among the most undervalued healthcare stocks. Elevance Health, Inc. (NYSE:ELV) is a major U.S. healthcare company, known for its insurance brands Anthem and WellPoint, and its growing Carelon health services arm. It serves around 45.6 million medical plan members and is recognized for integrating technology and value-based care to improve healthcare delivery. The company is facing increased healthcare utilization and rising medical costs, especially in the ACA and Medicaid segments. This has led to a downgrade in full-year 2025 earnings. A 'market-wide morbidity shift' is evident, with new ACA enrollees using emergency services at nearly double the rate of commercial members, and Medicaid patients showing higher acuity due to redeterminations. Amid these challenges, some investors see Elevance Health, Inc. (NYSE:ELV) as one of the most undervalued stocks in the healthcare sector, given its long-term positioning and strategic adjustments. The company expects a surge in elective procedures by Q4 2025 as members act ahead of expiring tax credits in 2026 that could raise their out-of-pocket costs. To address these pressures, the business is ramping up AI-driven tools for risk detection, care coordination, and operational efficiency. It's also expanding value-based care contracts, particularly in behavioral health and oncology, with over one-third of benefit expenses tied to risk-sharing models. The company is adjusting pricing strategies for ACA plans and advocating for Medicaid access amid potential regulatory changes. A healthcare professional discussing a treatment plan with a patient in an outpatient clinic. Though total membership fell by 212,000 in Q2 due to Medicaid attrition, the Medicare Advantage segment continues to grow. Elevance Health, Inc. (NYSE:ELV) is prioritizing long-term financial stability over aggressive member growth as it navigates rising costs, shifting regulations, and post-pandemic care patterns. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


CNN
33 minutes ago
- CNN
WSJ: Kennedy expected to dismiss expert panel on preventive care
Federal agencies WellnessFacebookTweetLink Follow US Health and Human Services Secretary Robert F. Kennedy Jr. plans to remove the expert advisers who make up a federal panel on preventive health care, the Wall Street Journal reported Friday. The future of the US Preventive Services Task Force has been in doubt since HHS called off this month's meeting of the nonpolitical advisory group. 'No final decision has been made on how the USPSTF can better support HHS' mandate to Make America Healthy Again,' HHS spokesperson Andrew Nixon told CNN on Friday. The 16-member task force was established in 1984 and provides recommendations about preventive services, such as screenings for cancer and various disorders and counseling, that help make Americans aware of illnesses and conditions earlier, when they can be easier and less expensive to treat. The Affordable Care Act mandates that those services are provided without charge to patients. Kennedy's control over the task force was recently solidified by the US Supreme Court. Last month, in a case challenging a popular provision of the Affordable Care Act, the justices upheld the constitutionality of the task force, which recommends preventive health care services that insurers must cover at no cost. Both the Biden and Trump administrations argued that the task force was properly set up — and therefore, its recommendations should be upheld — because the Health and Human Services secretary was able to name and fire its members. Since taking over at HHS, Kennedy has pushed to reshape the health agencies and expunge them of what he has called longtime health-care industry influence on policies. Last month, he dismissed the 17-member vaccine advisory committee for the US Centers for Disease Control and Prevention and, two days later, named eight new picks. Several of the new members of the Advisory Committee on Immunization Practices have questioned vaccine safety; two have testified in court against vaccine manufacturers.